Funding for today’s life science ventures is often granted for disruptive innovations that bear intrinsic risks and aim to fundamentally change current healthcare practices. So how do we manage high-risk R&D projects while developing them as a robust pipeline of assets?
At this BioForum, international expert Dr Kurt Stoeckli, President of the NDA Advisory Board (UK), will appear virtually to discuss:
The key role of risk-based assessment, related mitigation strategies and the importance of early implementation in the development process
Critical success factors for translating scientific innovation into clinically meaningful milestones
Strategic considerations for seeking expediting approval and reaching the market in a timely manner
Early consideration of market access criteria and interactions with regulatory authorities
Exploring the development of novel cancer therapeutics, Oncology One CEO, Dr Joanne Boag, will discuss some of the key challenges and opportunities that exist in the translation of innovative research projects, and what’s needed to unlock the potential of medical research in Australia.
Minomic International CEO, Dr Brad Walsh (Sydney), will also share his insights and some key lessons he has learned through bringing innovations from the lab bench to the marketplace.
This BioForum is part of our BioPharma Masterclass 1: Creating a Value Story for Your Product. Click here to learn more and register.
Click here to learn more about this year’s BioPharma Masterclass Series.
Date: Tuesday 22 March 2022
Time (AEDT): 4:00pm to 5:30pm – Presentations and Q&A / 5:30pm to 6:30pm – Networking (in-person guests)
In the event of postponement due to Government restrictions, registrations will be carried forward to a new date. Should the event be cancelled, or you are unable to attend on the rescheduled date, a full refund will be made available.
This event is sponsored by the State Government of Victoria, DJPR.
Our COVID-Safe Practices: In line with current COVID-19 restrictions in Victoria and ACMI’s COVID-Safe plan, in-person ticket allocation for this event is limited and adheres to the current Government restrictions applied to indoor event spaces. To keep BioMelbourne Network events safe for our members and the greater Victorian community, this event will include measures such as physical distancing, QR code check-in and enhanced hygiene and sanitation processes. Further details will be made available to registered guests via our event webpage and final confirmation email.
Guests Attending In-Person: Each attendee is asked to do a symptom self-assessment prior to leaving home. We ask that you DO NOT attend this event in-person if you are feeling unwell, have any symptoms of COVID-19, are awaiting results of a COVID-19 test or are required to self-isolate or quarantine at the time of the event. Symptoms of COVID-19 include cough, fever, sore throat, fatigue and shortness of breath. If you cannot attend in-person for these reasons, you may receive a full refund or partial refund plus virtual ticket. We ask that all in-person attendees act in a considerate and respectful manner towards our speakers, fellow guests, ACMI staff and BioMelbourne Network staff:
On arrival, all guests must scan in via the QR codes displayed at the venue entrance.
Maintain adequate physical distance between yourself and others, where possible.
Refrain from unnecessary physical contact, such as hand shaking.
Minimise movement by staying within your allocated spaces or seats, where practical.
Observe all COVID-Safe signage and practices at the venue.
Adhere to requirements for face covering, observe cough etiquette and personal hygiene measures.
Dr Kurt Stoeckli, President, NDA Advisory Board (UK)
Kurt is a seasoned healthcare executive with industry experience and track record in R&D of biopharmaceuticals. Immunologist and chemist by training, he has held positions of increasing responsibilities (global TA head, CSO), both in large pharmaceutical companies (Novartis, SANOFI) and in biotech. As global TA head of immunology and head of the biologics division at SANOFI, he succeeded in advancing several innovative medicines from research to market, as a result of internal research, or in collaboration with biotech partners. He has been involved in the development of dupilumab (DUPIXENT).
In April 2020 he joined the NDA group, a global development and regulatory consultancy, as the president of NDA’s advisory board, a distinguished expert panel of ex-regulators and former industry executives. In this role, Kurt sets the strategy to further develop capabilities and activities of NDA’s advisory services.
Kurt brings extensive business acumen and accomplishments, ranging from pre-clinical, clinical stages to the submission and approval of assets; he is familiar with scientific, medical, ethical, technical, regulatory and commercial success factors in life science.
Dr Joanne Boag, CEO, Oncology One
Dr Joanne Boag has more than 15 years-experience working in the life sciences sector developing health and medical research products and services.
Prior to joining Oncology One in November 2020, Joanne was Director of Business Development at a commercial stage digital health company. In this role, she was responsible for driving execution of the company’s business partnering strategy and leading the implementation of key business partnering projects, including supporting all aspects of upstream business development and leading downstream service delivery.
Previously, Joanne has worked at an ASX-listed diagnostic company and medical research institutions, where she led successful outcomes in research innovation and commercialisation, raising significant funding through equity financing and grants, facilitated collaborations with industry and academic partners and was responsible for the strategic management of intellectual property portfolios.
Joanne is a Registered Australian Patent and Trade Mark Attorney and has a Bachelor of Science with Honours from Murdoch University and a PhD in molecular biology from the University of Western Australia.
Dr Brad Walsh, CEO & Executive Director, Minomic International
Dr Brad Walsh is Chief Executive Officer and an Executive Director of Minomic International Ltd, a Sydney-based commercialization stage in vitro diagnostic company specialising in cancer detection. He founded Minomic to bring to market an innovative test called MiCheck , that gives a risk score for a patient having aggressive prostate cancer. The test has specificity that is twice that of its only competitor meaning less unnecessary biopsies.
Dr Walsh has led Minomic’s scientific and business development, raising A$27 million and bringing the company to a point at which MiCheck is ready to launch in the US as an LDT and has a marketing team in place to commence the rollout. Additionally, the test has recently been launched in Australia. Dr Walsh has also developed a pipeline of potential new diagnostics for bladder and pancreatic cancer.
Dr Walsh’s career in biotechnology began with a PhD in protein chemistry. Over the following years he led research groups in government agencies, universities and hospitals and was a key part of the establishment of a major national research facility, APAF, before forming Minomic in 2007.
He continues to be active in research collaborations and academic supervision and was a joint recipient of one of Australia’s most prestigious science awards, a Eureka Prize, for Interdisciplinary Research in 2015. More recently Dr Walsh won first prize against a field of international competitors at the 2018 Innovation & Entrepreneurship Competition for Overseas High-Level Talents in Hangzhou, China.
He has co-authored over 100 peer reviewed papers and book chapters and seven patents. He is also a mentor for the IMNIS Program.
Dr Patricia Vietheer, Director, R&D Strategy & Planning, Biointelect
Patricia Vietheer has over 18 years of scientific experience in the Life Sciences industry. She holds a Bachelor of Science degree with First Class Honours from University of Queensland and a PhD in Microbiology at Monash University. She also holds an MBA majoring in Strategy & Planning at Deakin University. In 2015, Patricia completed the Molecules to Medicine Internship on Commercialization.
A specialist in infectious diseases, molecular biology and viral immunology, Patricia’s career began in the research laboratory working on the preclinical evaluation of a versatile vaccine platform collaborating with industry. She has since held a range of roles in research; business development, project management and program development where she has helped translate scientific ideas into public health solutions. Patricia’s deep experience in early-stage preclinical R&D especially in vaccine development, technology transfer and in vivo animal studies, has been instrumental in project planning and execution often working in cross-discipline, multi-country projects driving projects towards successful outcomes.
Patricia has been a recipient of multiple awards including the NHMRC Dora Lush BioMedical Award, Australian Defence Force Prince of Wales Award and the Australian Centre for HIV & Hepatitis Virology Young Investigator’s Award. She has made substantial contribution to numerous granted patents, co-authored multiple scientific publications in peer-reviewed journals and has presented at numerous national and international conferences.